메뉴 건너뛰기




Volumn 5, Issue 3, 2017, Pages

Egg-independent influenza vaccines and vaccine candidates

Author keywords

Cell culture; Synthetic influenza vaccine; Vaccination

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; POLIOMYELITIS VACCINE; VIRUS NUCLEOPROTEIN;

EID: 85025441208     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines5030018     Document Type: Review
Times cited : (54)

References (43)
  • 1
    • 85025476425 scopus 로고    scopus 로고
    • Influenza Web Page., (accessed on 5 September 2016)
    • World Health Organization. Influenza Web Page. Available online: http://www.who.int/mediacentre/ factsheets/fs211/en/ (accessed on 5 September 2016).
  • 2
    • 85025475688 scopus 로고    scopus 로고
    • Weekly epidemiological record Relevé épidémiologique hebdomadaire
    • World Health Organization (WHO). Weekly epidemiological record Relevé épidémiologique hebdomadaire. ANNÉE 2014, 89, 245–256.
    • (2014) ANNÉE , vol.89 , pp. 245-256
  • 4
    • 59049093098 scopus 로고    scopus 로고
    • The influenza virus enigma
    • Salomon, R.; Webster, R.G. The influenza virus enigma. Cell 2009, 3, 402–410. [CrossRef] [PubMed]
    • (2009) Cell , vol.3 , pp. 402-410
    • Salomon, R.1    Webster, R.G.2
  • 5
    • 0037135669 scopus 로고    scopus 로고
    • Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control
    • Hilleman, M.R. Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control. Vaccine 2002, 20, 3068–3087. [CrossRef]
    • (2002) Vaccine , vol.20 , pp. 3068-3087
    • Hilleman, M.R.1
  • 6
    • 85025430557 scopus 로고    scopus 로고
    • (accessed on 22 May 2017)
    • European Centre for Disease Prevention and Control. Available online: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx (accessed on 22 May 2017).
  • 7
    • 0032078697 scopus 로고    scopus 로고
    • Development of a mammalian cell (Vero) derived candidate influenza virus vaccine
    • Kistner, O.; Barrett, P.N.; Mundt, W.; Reiter, M.; Schober-Bendixen, S.; Dorner, F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16, 960–968. [CrossRef]
    • (1998) Vaccine , vol.16 , pp. 960-968
    • Kistner, O.1    Barrett, P.N.2    Mundt, W.3    Reiter, M.4    Schober-Bendixen, S.5    Dorner, F.6
  • 8
    • 77953630380 scopus 로고    scopus 로고
    • Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
    • Pandey, A.; Singh, N.; Sambhara, S.; Mittal, S.K. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin 2010, 6, 178–188. [CrossRef] [PubMed]
    • (2010) Hum. Vaccin , vol.6 , pp. 178-188
    • Pandey, A.1    Singh, N.2    Sambhara, S.3    Mittal, S.K.4
  • 9
    • 85025441001 scopus 로고    scopus 로고
    • (accessed on 24 June 2017)
    • Centers for Disease Control and Prevention. How Influenza (Flu) Vaccines Are Made. Available online: https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm (accessed on 24 June 2017).
    • How Influenza (Flu) Vaccines are Made
  • 10
    • 85025443579 scopus 로고    scopus 로고
    • (accessed on 24 June 2017)
    • Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Total Doses Distributed. Available online: https://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm (accessed on 24 June 2017).
    • Seasonal Influenza Vaccine Total Doses Distributed
  • 11
    • 84994008683 scopus 로고    scopus 로고
    • History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines
    • Barberis, I.; Myles, P.; Ault, S.K.; Bragazzi, N.L.; Martini, M. History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines. J. Prev. Med. Hyg. 2016, 57, 115–120.
    • (2016) J. Prev. Med. Hyg , vol.57 , pp. 115-120
    • Barberis, I.1    Myles, P.2    Ault, S.K.3    Bragazzi, N.L.4    Martini, M.5
  • 12
    • 0029162495 scopus 로고
    • Cell culture as a substrate for the production of influenza vaccines: Memorandum from a WHO meeting
    • World Health Organization (WHO). Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 1995, 73, 431–435.
    • (1995) Bull. World Health Organ , vol.73 , pp. 431-435
  • 13
    • 65649125562 scopus 로고    scopus 로고
    • Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines
    • Barrett, P.N.; Mundt, W.; Kistner, O.; Howard, M.K. Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 2009, 8, 607–618. [CrossRef] [PubMed]
    • (2009) Expert Rev. Vaccines , vol.8 , pp. 607-618
    • Barrett, P.N.1    Mundt, W.2    Kistner, O.3    Howard, M.K.4
  • 14
    • 84865414271 scopus 로고    scopus 로고
    • Preflucel®: A Vero-cell culture-derived trivalent influenza vaccine
    • Chan, C.Y.; Tambyah, P.A. Preflucel®: A Vero-cell culture-derived trivalent influenza vaccine. Expert Rev. Vaccines 2012, 11, 759–773. [CrossRef] [PubMed]
    • (2012) Expert Rev. Vaccines , vol.11 , pp. 759-773
    • Chan, C.Y.1    Tambyah, P.A.2
  • 16
    • 77956231719 scopus 로고    scopus 로고
    • Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine
    • Onions, D.; Egan, W.; Jarrett, R.; Novicki, D.; Gregersen, J.P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010, 38, 544–551. [CrossRef] [PubMed]
    • (2010) Biologicals , vol.38 , pp. 544-551
    • Onions, D.1    Egan, W.2    Jarrett, R.3    Novicki, D.4    Gregersen, J.P.5
  • 17
    • 0028860812 scopus 로고
    • Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: Implications for vaccine manufacture
    • Robertson, J.S.; Cook, P.; Attwell, A.M.; Williams, S.P. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: Implications for vaccine manufacture. Vaccine 1995, 13, 1583–1588. [CrossRef]
    • (1995) Vaccine , vol.13 , pp. 1583-1588
    • Robertson, J.S.1    Cook, P.2    Attwell, A.M.3    Williams, S.P.4
  • 20
    • 67449102487 scopus 로고    scopus 로고
    • Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)
    • Doroshenko, A.; Halperin, S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 2009, 8, 679–688. [CrossRef] [PubMed]
    • (2009) Expert Rev. Vaccines , vol.8 , pp. 679-688
    • Doroshenko, A.1    Halperin, S.A.2
  • 21
    • 85025455952 scopus 로고    scopus 로고
    • (accessed on 24 May 2017)
    • U.S. Food & Drug Administration. Vaccines, Blood & Biologics. Available online: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328684.htm (accessed on 24 May 2017).
  • 23
    • 84866497171 scopus 로고    scopus 로고
    • Prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic
    • Reynales, H.; Astudillo, P.; de Vallière, S.; Hatz, C.; Schlagenhauf, P.; Rath, B.; Velentgas, P.; Fariña, A.; Sales-Carmona, V.; Groth, N. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. Vaccine 2012, 30, 6436–6443. [CrossRef] [PubMed]
    • (2012) Vaccine , vol.30 , pp. 6436-6443
    • Reynales, H.1    Astudillo, P.2    De Vallière, S.3    Hatz, C.4    Schlagenhauf, P.5    Rath, B.6    Velentgas, P.7    Fariña, A.8    Sales-Carmona, V.9    Groth, N.A.10
  • 24
    • 85025453152 scopus 로고    scopus 로고
    • (accessed on 25 May 2017)
    • Celvapan—-H1N1 Pandemic Influenza Vaccine. Available online: www.drugdevelopment-echnology.com/projects/celvapan/ (accessed on 25 May 2017).
  • 26
    • 79952101274 scopus 로고    scopus 로고
    • Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: A multicentre, double-blind, randomised, placebo-controlled trial
    • Barrett, P.N.; Berezuk, G.; Fritsch, S.; Aichinger, G.; Hart, M.K.; El-Amin, W.; Kistner, O.; Ehrlich, H.J. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377, 751–759. [CrossRef]
    • (2011) Lancet , vol.377 , pp. 751-759
    • Barrett, P.N.1    Berezuk, G.2    Fritsch, S.3    Aichinger, G.4    Hart, M.K.5    El-Amin, W.6    Kistner, O.7    Ehrlich, H.J.8
  • 29
    • 70649103793 scopus 로고    scopus 로고
    • Development of a simple and high-yielding fed-batch process for the production of influenza vaccines
    • Meghrous, J.; Mahmoud, W.; Jacob, D.; Chubet, R.; Cox, M.; Kamen, A.A. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. Vaccine 2009, 28, 309–316. [CrossRef] [PubMed]
    • (2009) Vaccine , vol.28 , pp. 309-316
    • Meghrous, J.1    Mahmoud, W.2    Jacob, D.3    Chubet, R.4    Cox, M.5    Kamen, A.A.6
  • 31
    • 77951671015 scopus 로고    scopus 로고
    • Vaccines Europe 2009
    • Mukhopadhyay, T.K. Vaccines Europe 2009. Expert Rev. Vaccines 2010, 9, 125–128. [CrossRef] [PubMed]
    • (2010) Expert Rev. Vaccines , vol.9 , pp. 125-128
    • Mukhopadhyay, T.K.1
  • 33
    • 84897110525 scopus 로고    scopus 로고
    • Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults
    • Cummings, J.F.; Guerrero, M.L.; Moon, J.E.; Waterman, P.; Nielsen, R.K.; Jefferson, S.; Gross, F.L.; Hancock, K.; Katz, J.M.; Yusibov, V. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults. Vaccine 2014, 32, 2251–2259. [CrossRef] [PubMed]
    • (2014) Vaccine , vol.32 , pp. 2251-2259
    • Cummings, J.F.1    Guerrero, M.L.2    Moon, J.E.3    Waterman, P.4    Nielsen, R.K.5    Jefferson, S.6    Gross, F.L.7    Hancock, K.8    Katz, J.M.9    Yusibov, V.10
  • 34
    • 66749137687 scopus 로고    scopus 로고
    • Vaccination strategies and vaccine formulation for epidemic and pandemic influenza control
    • Kreijtz, J.H.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination strategies and vaccine formulation for epidemic and pandemic influenza control. Hum. Vaccines 2009, 5, 126–135. [CrossRef]
    • (2009) Hum. Vaccines , vol.5 , pp. 126-135
    • Kreijtz, J.H.1    Osterhaus, A.D.2    Rimmelzwaan, G.F.3
  • 37
    • 84928825136 scopus 로고    scopus 로고
    • Emerging influenza viruses and the prospect of a universal influenza virus vaccine
    • Krammer, F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol. J. 2015, 10, 690–701. [CrossRef] [PubMed]
    • (2015) Biotechnol. J. , vol.10 , pp. 690-701
    • Krammer, F.1
  • 38
    • 84959349464 scopus 로고    scopus 로고
    • Novel universal influenza virus vaccine approaches
    • Krammer, F. Novel universal influenza virus vaccine approaches. Curr. Opin. Virol. 2016, 17, 95–103. [CrossRef] [PubMed]
    • (2016) Curr. Opin. Virol. , vol.17 , pp. 95-103
    • Krammer, F.1
  • 39
    • 67349117322 scopus 로고    scopus 로고
    • Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
    • Minor, P.D.; Engelhardt, O.G.; Wood, J.M.; Robertson, J.S.; Blayer, S.; Colegate, T.; Fabry, L.; Heldens, J.G.; Kino, Y.; Kistner, O.; et al. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27, 2907–2913. [CrossRef] [PubMed]
    • (2009) Vaccine , vol.27 , pp. 2907-2913
    • Minor, P.D.1    Engelhardt, O.G.2    Wood, J.M.3    Robertson, J.S.4    Blayer, S.5    Colegate, T.6    Fabry, L.7    Heldens, J.G.8    Kino, Y.9    Kistner, O.10
  • 40
    • 44749090301 scopus 로고    scopus 로고
    • A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine
    • Gregersen, J.P. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008, 26, 3332–3340. [CrossRef] [PubMed]
    • (2008) Vaccine , vol.26 , pp. 3332-3340
    • Gregersen, J.P.1
  • 41
    • 0037095578 scopus 로고    scopus 로고
    • Influenza DNA vaccines
    • Ulmer, J.B. Influenza DNA vaccines. Vaccine 2002, 20, 74–76. [CrossRef]
    • (2002) Vaccine , vol.20 , pp. 74-76
    • Ulmer, J.B.1
  • 42
    • 84921676353 scopus 로고    scopus 로고
    • Rapid production of synthetic influenza vaccines
    • Dormitzer, P.R. Rapid production of synthetic influenza vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 237–273. [CrossRef] [PubMed]
    • (2015) Curr. Top. Microbiol. Immunol. , vol.386 , pp. 237-273
    • Dormitzer, P.R.1
  • 43
    • 18844389483 scopus 로고    scopus 로고
    • Influenza vaccines: Recent advances in production technologies
    • Bardiya, N.; Bae, J.H. Influenza vaccines: Recent advances in production technologies. Appl. Microbiol. Biotechnol. 2005, 67, 299–305. [CrossRef] [PubMed]
    • (2005) Appl. Microbiol. Biotechnol. , vol.67 , pp. 299-305
    • Bardiya, N.1    Bae, J.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.